GEOMETRY duo-1: A phase (Ph) Ib/II, multicenter trial of oral cMET inhibitor capmatinib (INC280) ± erlotinib vs platinum + pemetrexed in adult patients (pts) with epidermal growth factor receptor (EGFR)-mutated, cMET-amplified, locally advanced/metastatic non-small cell lung cancer (NSCLC) with acquired resistance to prior EGFR tyrosine kinase inhibitor (TKI) therapy.

Epidermal Growth ◽

Egfr Mutated

Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Combined with Chemoradiotherapy for the Treatment of Unresectable Locally Advanced Non-small Cell Lung Cancer

Haigan ◽

10.2482/haigan.46.261 ◽

2006 ◽

Vol 46 (3) ◽

pp. 261-265

Author(s):

Yuichiro Ohe

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Kinase Inhibitor ◽

Locally Advanced ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations

Investigational New Drugs ◽

10.1007/s10637-019-00732-4 ◽

2019 ◽

Vol 37 (6) ◽

pp. 1207-1217

Author(s):

Makoto Nishio ◽

Haruyasu Murakami ◽

Yuichiro Ohe ◽

Toyoaki Hida ◽

Hiroshi Sakai ◽

...

Keyword(s):

Lung Cancer ◽

Phase I Study ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Egfr Mutations ◽

Third Generation ◽

Small Cell Lung ◽

Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease

Journal of Thoracic Oncology ◽

10.1097/jto.0000000000000380 ◽

2015 ◽

Vol 10 (1) ◽

pp. 156-163 ◽

Cited By ~ 150

Author(s):

Petra Hoffknecht ◽

Amanda Tufman ◽

Thomas Wehler ◽

Theo Pelzer ◽

Rainer Wiewrodt ◽

...

Keyword(s):

Lung Cancer ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Leptomeningeal Disease ◽

Small Cell Lung ◽

Lung Cancer Patients ◽

Erbb Family Blocker ◽

PCN109 Cost Effectiveness of First Line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients: A Markov Model

Value in Health ◽

10.1016/j.jval.2011.08.1210 ◽

2011 ◽

Vol 14 (7) ◽

pp. A454 ◽

Cited By ~ 2

Author(s):

I. Borget ◽

A. Vergnenegre ◽

C. Chouaid

Keyword(s):

Lung Cancer ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

Nsclc Patients ◽

Egfr Mutated ◽

Inhibitor Treatment

Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?

The Korean Journal of Internal Medicine ◽

10.3904/kjim.2016.190 ◽

2017 ◽

Vol 32 (3) ◽

pp. 422-428 ◽

Cited By ~ 1

Author(s):

Yong Won Choi ◽

Jin-Hyuk Choi

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Clinical Significance of Sequential Treatment with Afatinib in the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Treatment of Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a3935 ◽

2019 ◽

Author(s):

N. Kobayashi ◽

H. Aiko ◽

C. Kamimaki ◽

N. Mikami ◽

S. Kubo ◽

...

Keyword(s):

Lung Cancer ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽

Tki Treatment ◽

Egfr Mutant

Pneumonitis in advanced non-small-cell lung cancer (NSCLC) patients (pts) treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI): Meta-analysis of 153 trial cohorts with 15,713 pts.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.e21223 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. e21223-e21223

Author(s):

Chong Hyun Suh ◽

Hyesun Park ◽

Kyung Won Kim ◽

Junhee Pyo ◽

Hiroto Hatabu ◽

...

Keyword(s):

Lung Cancer ◽

Kinase Inhibitor ◽

Meta Analysis ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽

Nsclc Patients

481TiP Checkmate 722: A phase 3 trial of nivolumab with chemotherapy or ipilimumab vs chemotherapy in epidermal growth factor receptor (EGFR)-mutation, T790M-negative stage IV or recurrent non-small cell lung cancer (NSCLC) after EGFR tyrosine kinase inhibitor (TKI) therapy

Annals of Oncology ◽

10.1093/annonc/mdw594.045 ◽

2016 ◽

Vol 27 (suppl_9) ◽

Cited By ~ 2

Author(s):

K. Nakagawa ◽

J.C-H. Yang ◽

K. Park ◽

Y. Ohe ◽

Y-L. Wu ◽

...

Keyword(s):

Lung Cancer ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Stage Iv ◽

Small Cell ◽

Small Cell Lung ◽

Phase 3 ◽

Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer

Oncology Reports ◽

10.3892/or.2012.1741 ◽

2012 ◽

Cited By ~ 1

Author(s):

Qiong Zhao

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽

Egfr Mutated

Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial)

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hyz023 ◽

2019 ◽

Vol 49 (6) ◽

pp. 554-558 ◽

Cited By ~ 5

Author(s):

Kazuhiro Usui ◽

Takuma Yokoyama ◽

Go Naka ◽

Hiroo Ishida ◽

Kazuma Kishi ◽

...

Keyword(s):

Lung Cancer ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽

Egfr Mutant ◽

Inhibitor Treatment